Britta Weigelt Selected Research

Fibrocystic Breast Disease (Chronic Cystic Mastitis)

1/2017	Genetic analysis of microglandular adenosis and acinic cell carcinomas of the breast provides evidence for the existence of a low-grade triple-negative breast neoplasia family.
4/2016	Microglandular adenosis associated with triple-negative breast cancer is a neoplastic lesion of triple-negative phenotype harbouring TP53 somatic mutations.
1/2013	Microglandular adenosis: a non-obligate precursor of triple-negative breast cancer?

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Britta Weigelt Research Topics

Disease

108	Neoplasms (Cancer) 11/2022 - 06/2002
53	Breast Neoplasms (Breast Cancer) 01/2022 - 08/2004
17	Carcinoma (Carcinomatosis) 01/2022 - 08/2004
9	Ovarian Neoplasms (Ovarian Cancer) 01/2022 - 11/2017
9	Endometrial Neoplasms (Endometrial Cancer) 10/2020 - 05/2011
6	Triple Negative Breast Neoplasms 01/2021 - 01/2011
5	Neoplasm Metastasis (Metastasis) 12/2021 - 01/2014
5	Adenocarcinoma 01/2021 - 05/2011
5	Papillary Carcinoma 01/2020 - 02/2012
4	Ductal Carcinoma 12/2014 - 11/2009
3	Hereditary Nonpolyposis Colorectal Neoplasms (Hereditary Nonpolyposis Colorectal Cancer) 01/2022 - 01/2020
3	Sarcoma (Soft Tissue Sarcoma) 01/2022 - 01/2016
3	Lobular Carcinoma 01/2021 - 07/2013
3	Mucinous Adenocarcinoma (Mucinous Carcinoma) 01/2021 - 01/2019
3	Acinar Cell Carcinoma 12/2019 - 10/2015
3	Endometrioid Carcinoma 09/2017 - 04/2015
3	Fibrocystic Breast Disease (Chronic Cystic Mastitis) 01/2017 - 01/2013
2	Small Cell Carcinoma 10/2022 - 10/2021
2	Fibroadenoma 02/2022 - 11/2015
2	Lung Neoplasms (Lung Cancer) 01/2022 - 01/2021
2	Squamous Cell Carcinoma (Epidermoid Carcinoma) 01/2022 - 01/2016
2	Carcinogenesis 01/2022 - 01/2020
2	Residual Neoplasm 01/2022 - 08/2015
2	Adenoid Cystic Carcinoma (Cylindroma) 01/2021 - 03/2010
2	Adenomyoepithelioma 01/2021 - 01/2018
2	Noninfiltrating Intraductal Carcinoma (DCIS) 01/2021 - 05/2014
2	Microsatellite Instability 01/2020 - 12/2018
2	DNA Repair-Deficiency Disorders (Chromosome Instability Syndromes) 01/2020 - 01/2017
2	Brain Neoplasms (Brain Tumor) 04/2018 - 05/2011
2	Metaplasia 01/2017 - 03/2015
2	Disease Progression 01/2016 - 05/2011
2	Lymphatic Metastasis 01/2014 - 02/2012
1	Endometrial Stromal Sarcoma 01/2022
1	Squamous Cell Carcinoma of Head and Neck 01/2022
1	Colorectal Neoplasms (Colorectal Cancer) 01/2022
1	Inflammation (Inflammations) 01/2022
1	Chromosomal Instability (Chromosome Stability) 01/2022

Drug/Important Bio-Agent (IBA)

24	DNA (Deoxyribonucleic Acid)IBA 01/2022 - 08/2004
22	Estrogen ReceptorsIBA 01/2022 - 08/2006
13	Proteins (Proteins, Gene)FDA Link 01/2022 - 02/2013
13	Phenobarbital (Luminal)FDA Link 02/2017 - 08/2006
12	RNA (Ribonucleic Acid)IBA 11/2022 - 12/2014
9	Biological ProductsIBA 01/2022 - 08/2006
8	Hormones (Hormone)IBA 01/2022 - 07/2009
8	Progesterone Receptors (Progesterone Receptor)IBA 01/2020 - 01/2007
7	Biomarkers (Surrogate Marker)IBA 01/2022 - 04/2011
6	Formaldehyde (Formol)FDA Link 10/2019 - 01/2016
6	ParaffinIBA 10/2019 - 01/2016
5	Lapatinib (GW572016)FDA Link 01/2020 - 07/2010
5	Trastuzumab (Herceptin)FDA Link 01/2020 - 07/2010
4	Immune Checkpoint InhibitorsIBA 01/2022 - 01/2020
4	MucinsIBA 01/2021 - 01/2019
4	AntibodiesIBA 01/2020 - 11/2010
4	Cadherins (E-Cadherin)IBA 01/2018 - 11/2010
3	B7-H1 AntigenIBA 01/2022 - 01/2021
3	Transcription Factors (Transcription Factor)IBA 01/2022 - 02/2017
3	Mitogen-Activated Protein KinasesIBA 01/2022 - 10/2018
3	Exonucleases (3' 5' Exonuclease)IBA 01/2020 - 04/2015
3	Poly(ADP-ribose) Polymerase InhibitorsIBA 11/2017 - 05/2011
3	Phosphatidylinositols (Phosphatidylinositol)IBA 05/2014 - 01/2012
3	Messenger RNA (mRNA)IBA 06/2010 - 06/2002
3	OligonucleotidesIBA 01/2010 - 01/2007
2	PlatinumIBA 11/2022 - 11/2017
2	Telomerase (Telomerase Reverse Transcriptase)IBA 05/2022 - 02/2022
2	Mediator ComplexIBA 02/2022 - 11/2015
2	MART-1 AntigenIBA 01/2022 - 01/2021
2	Adenosine Triphosphatases (ATPase)IBA 01/2022 - 10/2021
2	Cyclin D1IBA 01/2020 - 11/2010
2	human ERBB2 proteinIBA 01/2020 - 01/2017
2	Monoclonal AntibodiesIBA 01/2020 - 01/2019
2	Hematoxylin (Haematoxylon)IBA 01/2020 - 04/2015
2	Eosine Yellowish-(YS) (Eosin)IBA 01/2020 - 04/2015
2	CateninsIBA 01/2019 - 07/2013
2	Codon (Codons)IBA 01/2018 - 01/2018
2	Cell-Free Nucleic AcidsIBA 01/2018 - 11/2017
2	ClaudinsIBA 01/2017 - 03/2015
2	Phosphotransferases (Kinase)IBA 06/2016 - 03/2012
2	Proteasome Endopeptidase Complex (Proteasome)IBA 01/2016 - 08/2012
2	Circulating Tumor DNAIBA 08/2015 - 10/2013
1	AdiponectinIBA 01/2022
1	Carboplatin (JM8)FDA LinkGeneric 01/2022
1	Verteporfin (Visudyne)FDA Link 01/2022
1	Cathepsin KIBA 01/2022
1	C-Reactive ProteinIBA 01/2022
1	Interleukin-6 (Interleukin 6)IBA 01/2022
1	LigandsIBA 01/2022
1	EpitopesIBA 01/2022
1	Sex Hormone-Binding GlobulinIBA 01/2022
1	LeptinIBA 01/2022
1	Heat-Shock Proteins (Heat-Shock Protein)IBA 01/2022
1	SmokeIBA 01/2022

Therapy/Procedure

38	Therapeutics 11/2022 - 06/2010
10	Drug Therapy (Chemotherapy) 10/2022 - 09/2009
4	Neoadjuvant Therapy 10/2022 - 08/2015
4	Radiotherapy 01/2021 - 05/2011
3	Immunotherapy 01/2022 - 01/2021
3	Precision Medicine 10/2017 - 01/2014
1	Adjuvant Chemotherapy 10/2022
1	Cystectomy 10/2022
1	Chemoradiotherapy 10/2022